Analysis of Liquidity Ratios
Quarterly Data
Liquidity ratios measure the company ability to meet its short-term obligations.
Liquidity Ratios (Summary)
Humana Inc., liquidity ratios (quarterly data)
Based on: 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
- Liquidity Trends
- Over the observed periods, the current ratio generally demonstrates a fluctuating but overall stable trend, with values ranging from a high of 1.81 in September 2020 to a low of 1.35 in September 2022. Notably, after a decline through 2021 and into 2022, the ratio shows a recovery starting in late 2022 and continuing into mid-2024, reaching 1.76 in September 2024. This indicates a generally adequate ability to cover short-term liabilities with current assets, with some periods of relative weakening in liquidity.
- Quick Ratio Analysis
- The quick ratio exhibits a pattern similar to the current ratio but at consistently lower levels, reflecting the exclusion of inventory from liquid assets. It peaked at 1.47 in September 2020 before declining to a low around 1.13 in September 2022. Subsequent quarters show improvement, climbing steadily to 1.40 by September 2024. This recovery suggests enhanced liquid asset coverage of current liabilities after a dormant phase.
- Cash Ratio Observations
- The cash ratio shows less volatility compared to the current and quick ratios but indicates a slight downward trend from its peak of 1.39 in September 2020 to a low near 1.02 in mid-2022. From this point, it demonstrates a gradual increase, peaking again at 1.29 in September 2024. This pattern suggests a conservative management of cash assets, maintaining coverage of immediate debts above the benchmark of 1, thereby ensuring strong short-term cash liquidity.
- Overall Liquidity Insights
- The three liquidity measures collectively reflect a period of stronger liquidity in early 2020, followed by a noticeable weakening through 2021 into mid-2022. Thereafter, a recovery trend is apparent across all ratios extending into 2024. The fluctuating but resilient nature of these ratios indicates prudent management of liquid assets with a capacity to respond to changing liquidity needs while maintaining sufficient buffers to meet short-term obligations.
Current Ratio
Humana Inc., current ratio calculation (quarterly data)
| Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||
| Current assets | 32,926) | 32,858) | 32,796) | 29,986) | 38,253) | 38,759) | 37,532) | 26,183) | 33,711) | 27,217) | 26,840) | 24,893) | 25,815) | 25,790) | 25,526) | 23,641) | 27,031) | 27,868) | 24,551) | ||||||
| Current liabilities | 18,727) | 19,790) | 19,689) | 18,872) | 27,823) | 28,279) | 26,942) | 17,178) | 25,051) | 17,839) | 17,532) | 15,331) | 15,027) | 15,051) | 15,300) | 13,394) | 14,905) | 16,455) | 14,830) | ||||||
| Liquidity Ratio | |||||||||||||||||||||||||
| Current ratio1 | 1.76 | 1.66 | 1.67 | 1.59 | 1.37 | 1.37 | 1.39 | 1.52 | 1.35 | 1.53 | 1.53 | 1.62 | 1.72 | 1.71 | 1.67 | 1.77 | 1.81 | 1.69 | 1.66 | ||||||
| Benchmarks | |||||||||||||||||||||||||
| Current Ratio, Competitors2 | |||||||||||||||||||||||||
| Abbott Laboratories | 1.60 | 1.68 | 1.60 | 1.64 | 1.74 | 1.64 | 1.68 | 1.63 | 1.86 | 2.01 | 1.85 | 1.85 | 1.83 | 1.79 | 1.75 | — | — | — | — | ||||||
| Elevance Health Inc. | 1.50 | 1.49 | 1.37 | 1.44 | 1.41 | 1.44 | 1.43 | 1.40 | 1.35 | 1.36 | 1.36 | 1.47 | 1.48 | 1.49 | 1.57 | — | — | — | — | ||||||
| Intuitive Surgical Inc. | 4.30 | 5.15 | 5.55 | 4.76 | 5.31 | 5.22 | 5.26 | 4.40 | 5.10 | 5.36 | 5.22 | 5.08 | 5.58 | 5.99 | 6.71 | — | — | — | — | ||||||
| Medtronic PLC | 2.30 | 2.29 | 2.42 | 2.39 | 1.76 | 1.76 | 1.58 | 1.86 | 2.61 | 2.91 | 2.89 | 2.65 | 2.10 | 2.16 | 1.87 | — | — | — | — | ||||||
| UnitedHealth Group Inc. | 0.91 | 0.88 | 0.85 | 0.79 | 0.80 | 0.80 | 0.81 | 0.77 | 0.82 | 0.77 | 0.78 | 0.79 | 0.77 | 0.77 | 0.74 | — | — | — | — | ||||||
Based on: 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
1 Q3 2024 Calculation
Current ratio = Current assets ÷ Current liabilities
= 32,926 ÷ 18,727 = 1.76
2 Click competitor name to see calculations.
- Current Assets
- The current assets exhibit notable fluctuations over the observed periods. Beginning at approximately $24.6 billion in the first quarter of 2020, they broadly increased with some volatility, peaking at about $38.8 billion in the third quarter of 2023. Following this peak, a decline is observed, with values dropping to nearly $33 billion by the third quarter of 2024. The trend indicates periods of significant growth interspersed with contractions, suggesting changes in liquidity management or operational cycles.
- Current Liabilities
- Current liabilities also display considerable variability, starting at around $14.8 billion in the first quarter of 2020. There is a general upward trend reaching a maximum of approximately $28.3 billion in the second quarter of 2023 before decreasing substantially thereafter to about $18.7 billion by the third quarter of 2024. The fluctuations in liabilities appear somewhat aligned with the movements in current assets, though liabilities show a sharper rise and subsequent decline in the recent quarters, potentially reflecting shifts in short-term obligations or payable management.
- Current Ratio
- The liquidity ratio starts relatively strong at 1.66 in the first quarter of 2020, showing stability around this level through the early quarters of 2021. There is a noticeable decrease to a low of approximately 1.35 in the third quarter of 2022, implying a temporary tightening in liquidity or relative increase in liabilities. However, the ratio recovers gradually thereafter, rising to around 1.76 by the third quarter of 2024. Overall, these ratios indicate the company has maintained a current ratio consistently above 1, suggesting adequate short-term liquidity to cover current liabilities despite some periods of tighter liquidity conditions.
- Summary of Trends
- The data reflects an environment of dynamic changes in working capital components. Current assets and liabilities both demonstrate increases with sharp peaks during 2022 and early 2023, followed by declines towards 2024. The current ratio trend indicates a maintained ability to meet short-term obligations, even as the company experienced cyclical shifts in liquidity. The fluctuations may point to operational adjustments, changes in credit terms, or cash flow timing variations, which impact the balance of assets and liabilities on a quarterly basis.
Quick Ratio
Humana Inc., quick ratio calculation (quarterly data)
| Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||
| Cash and cash equivalents | 5,116) | 5,501) | 5,910) | 4,694) | 15,148) | 16,214) | 13,735) | 5,061) | 13,558) | 5,153) | 4,864) | 3,394) | 4,304) | 3,378) | 3,877) | 4,673) | 7,985) | 7,163) | 6,054) | ||||||
| Investment securities | 19,033) | 17,424) | 16,697) | 16,626) | 15,145) | 15,251) | 14,932) | 13,881) | 13,124) | 13,037) | 13,092) | 13,192) | 13,719) | 13,471) | 13,251) | 12,554) | 12,741) | 12,836) | 11,104) | ||||||
| Receivables, less allowances | 2,144) | 4,090) | 3,925) | 2,035) | 1,824) | 1,429) | 3,107) | 1,674) | 1,609) | 3,369) | 3,174) | 1,814) | 1,879) | 2,438) | 2,196) | 1,138) | 1,135) | 2,238) | 2,009) | ||||||
| Total quick assets | 26,293) | 27,015) | 26,532) | 23,355) | 32,117) | 32,894) | 31,774) | 20,616) | 28,291) | 21,559) | 21,130) | 18,400) | 19,902) | 19,287) | 19,324) | 18,365) | 21,861) | 22,237) | 19,167) | ||||||
| Current liabilities | 18,727) | 19,790) | 19,689) | 18,872) | 27,823) | 28,279) | 26,942) | 17,178) | 25,051) | 17,839) | 17,532) | 15,331) | 15,027) | 15,051) | 15,300) | 13,394) | 14,905) | 16,455) | 14,830) | ||||||
| Liquidity Ratio | |||||||||||||||||||||||||
| Quick ratio1 | 1.40 | 1.37 | 1.35 | 1.24 | 1.15 | 1.16 | 1.18 | 1.20 | 1.13 | 1.21 | 1.21 | 1.20 | 1.32 | 1.28 | 1.26 | 1.37 | 1.47 | 1.35 | 1.29 | ||||||
| Benchmarks | |||||||||||||||||||||||||
| Quick Ratio, Competitors2 | |||||||||||||||||||||||||
| Abbott Laboratories | 1.00 | 1.02 | 0.95 | 1.00 | 1.04 | 1.00 | 1.07 | 1.06 | 1.22 | 1.33 | 1.21 | 1.28 | 1.25 | 1.19 | 1.16 | — | — | — | — | ||||||
| Elevance Health Inc. | 1.34 | 1.32 | 1.23 | 1.30 | 1.29 | 1.32 | 1.31 | 1.27 | 1.21 | 1.22 | 1.23 | 1.33 | 1.33 | 1.35 | 1.43 | — | — | — | — | ||||||
| Intuitive Surgical Inc. | 3.21 | 3.94 | 4.31 | 3.83 | 4.44 | 4.36 | 4.30 | 3.56 | 4.19 | 4.49 | 4.40 | 4.34 | 4.66 | 5.12 | 5.76 | — | — | — | — | ||||||
| Medtronic PLC | 1.46 | 1.42 | 1.51 | 1.54 | 1.18 | 1.18 | 1.01 | 1.30 | 1.87 | 2.07 | 2.06 | 1.91 | 1.58 | 1.63 | 1.37 | — | — | — | — | ||||||
| UnitedHealth Group Inc. | 0.83 | 0.81 | 0.79 | 0.73 | 0.75 | 0.74 | 0.75 | 0.70 | 0.77 | 0.71 | 0.72 | 0.72 | 0.71 | 0.71 | 0.68 | — | — | — | — | ||||||
Based on: 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
1 Q3 2024 Calculation
Quick ratio = Total quick assets ÷ Current liabilities
= 26,293 ÷ 18,727 = 1.40
2 Click competitor name to see calculations.
- Total Quick Assets
- Total quick assets exhibited notable fluctuations over the observed periods. Initially, there was a decline from approximately 22.2 billion to 18.4 billion in the last quarter of 2020, followed by a recovery towards the end of 2022 where a peak exceeding 31 billion was recorded. Subsequently, a decrease occurred through 2023, with values ranging between roughly 23.3 billion and 32.9 billion, then stabilizing around 26.3 billion by the third quarter of 2024, indicating variability but a general tendency to maintain substantial liquidity reserves.
- Current Liabilities
- Current liabilities showed an overall increasing trend with periods of volatility. From about 14.5 billion at the end of the first quarter 2020, liabilities rose to a peak nearing 28.3 billion in mid-2023. After this apex, a decline was observed, falling back to approximately 18.7 billion by the third quarter of 2024. This pattern suggests episodic increases in obligations potentially linked to business cycles or strategic financial decisions, followed by partial reduction periods.
- Quick Ratio
- The quick ratio, reflecting short-term liquidity, remained consistently above 1.0 throughout the timeframe, indicating the company maintained the ability to cover current liabilities with its quick assets. However, the ratio generally declined from an initial 1.29 in early 2020 to a low of 1.13 by the third quarter of 2022. Thereafter, it recovered steadily to reach approximately 1.4 by the third quarter of 2024. This recovery suggests an improvement in liquidity management or asset composition that enhances the company’s immediate financial stability after a period of relative tightening.
- Summary of Trends
- Overall, the data reflects a dynamic liquidity position characterized by periods of significant asset growth and fluctuating liabilities. Despite volatility, the quick ratio indicates the company consistently maintained a buffer over current liabilities, with improvements noted in the latter periods. This pattern may signify strategic adjustments in liquidity management and an emphasis on maintaining financial flexibility amid varying operational and market conditions.
Cash Ratio
Humana Inc., cash ratio calculation (quarterly data)
| Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||
| Cash and cash equivalents | 5,116) | 5,501) | 5,910) | 4,694) | 15,148) | 16,214) | 13,735) | 5,061) | 13,558) | 5,153) | 4,864) | 3,394) | 4,304) | 3,378) | 3,877) | 4,673) | 7,985) | 7,163) | 6,054) | ||||||
| Investment securities | 19,033) | 17,424) | 16,697) | 16,626) | 15,145) | 15,251) | 14,932) | 13,881) | 13,124) | 13,037) | 13,092) | 13,192) | 13,719) | 13,471) | 13,251) | 12,554) | 12,741) | 12,836) | 11,104) | ||||||
| Total cash assets | 24,149) | 22,925) | 22,607) | 21,320) | 30,293) | 31,465) | 28,667) | 18,942) | 26,682) | 18,190) | 17,956) | 16,586) | 18,023) | 16,849) | 17,128) | 17,227) | 20,726) | 19,999) | 17,158) | ||||||
| Current liabilities | 18,727) | 19,790) | 19,689) | 18,872) | 27,823) | 28,279) | 26,942) | 17,178) | 25,051) | 17,839) | 17,532) | 15,331) | 15,027) | 15,051) | 15,300) | 13,394) | 14,905) | 16,455) | 14,830) | ||||||
| Liquidity Ratio | |||||||||||||||||||||||||
| Cash ratio1 | 1.29 | 1.16 | 1.15 | 1.13 | 1.09 | 1.11 | 1.06 | 1.10 | 1.07 | 1.02 | 1.02 | 1.08 | 1.20 | 1.12 | 1.12 | 1.29 | 1.39 | 1.22 | 1.16 | ||||||
| Benchmarks | |||||||||||||||||||||||||
| Cash Ratio, Competitors2 | |||||||||||||||||||||||||
| Abbott Laboratories | 0.52 | 0.52 | 0.47 | 0.53 | 0.54 | 0.57 | 0.66 | 0.66 | 0.74 | 0.75 | 0.65 | 0.78 | 0.75 | 0.71 | 0.67 | — | — | — | — | ||||||
| Elevance Health Inc. | 0.90 | 0.86 | 0.82 | 0.87 | 0.90 | 0.92 | 0.91 | 0.86 | 0.87 | 0.86 | 0.86 | 0.95 | 0.97 | 0.97 | 1.08 | — | — | — | — | ||||||
| Intuitive Surgical Inc. | 2.52 | 3.20 | 3.49 | 3.15 | 3.86 | 3.77 | 3.59 | 2.90 | 3.50 | 3.78 | 3.58 | 3.66 | 3.98 | 4.42 | 5.04 | — | — | — | — | ||||||
| Medtronic PLC | 0.85 | 0.80 | 0.87 | 0.88 | 0.77 | 0.79 | 0.63 | 0.85 | 1.26 | 1.37 | 1.36 | 1.27 | 1.17 | 1.18 | 0.99 | — | — | — | — | ||||||
| UnitedHealth Group Inc. | 0.37 | 0.33 | 0.35 | 0.34 | 0.42 | 0.44 | 0.43 | 0.36 | 0.46 | 0.36 | 0.37 | 0.36 | 0.35 | 0.35 | 0.33 | — | — | — | — | ||||||
Based on: 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
1 Q3 2024 Calculation
Cash ratio = Total cash assets ÷ Current liabilities
= 24,149 ÷ 18,727 = 1.29
2 Click competitor name to see calculations.
The financial data reveals several trends and fluctuations in liquidity and liabilities over the examined periods. The total cash assets exhibit notable variability, with an initial increase from early 2020, peaking towards the end of 2022 and early 2023, followed by a decline and subsequent modest recovery in the first half of 2024. This pattern indicates episodic accumulation and utilization of cash reserves.
Current liabilities show a general upward trend from the beginning of 2020 through the end of 2022, reaching a peak in the third quarter of 2022, after which there is a significant decline. This reduction continues into mid-2024, suggesting an improvement in managing short-term obligations or possibly changes in operational or financing strategies.
The cash ratio remains consistently above 1.0 across all periods, indicating that the company maintains sufficient cash assets to cover its current liabilities. While there are fluctuations, the ratio stays within a relatively narrow range, peaking at 1.39 in the third quarter of 2020 and reaching a high of 1.29 in the third quarter of 2024. This stability signifies solid short-term liquidity management despite variations in cash assets and liabilities.
Overall, the data suggests a company maintaining a conservative liquidity position, with some periods of increased cash accumulation aligned with rising current liabilities, followed by phases of liability reduction and cash optimization. The oscillations in cash assets and liabilities may reflect operational cycles, strategic financial planning, or external economic factors impacting the company’s cash flow and liability management.